In patients 6, 8 and 9 we had concomitant SMARCB1 (INI1) loss and a TP53 missense mutation together with the inactivation of other tumor suppressors such as CDKN2A and RB1. Interestingly, patient 9 related closest to the group of epithelioid sarcoma despite harboring a TP53 mutation. This evidence concerns the gene CDKN2A and neoplasm.